A new study indicated that patients with metastatic renal cell carcinoma (mRCC) who had a history of hypertension did not show differences in overall survival (OS) in comparison with patients who had normal blood pressure. The study’s results were presented at the American Society of Clinical Oncology 2021 Genitourinary Cancers Symposium.
According to the study investigators, patients with certain comorbidities are often excluded from clinical trials. In this study, they performed a retrospective analysis of patients with mRCC with a focus on efficacy in the context of certain comorbidities that are often among clinical trial exclusion criteria. Efficacy outcomes of interest included survival, response, and progression. Data on treatment patterns and risk scores were also evaluated.
In a total study population of 198 patients, pazopanib was given to 42.42% of patients, sunitinib to 21.71%, cabozantinib to 13.64%, ipilimumab with nivolumab to 11.62%, and axitinib with pembrolizumab to 10.61%. Median time on first-line therapy was 5.17 months, and there was a median OS of 22.80 months across the study population.
There was a history of uncontrolled hypertension in the majority (71.72%) of patients qualifying for systemic therapy, while 28.28% did not have a history of hypertension. In an analysis of 165 patients, OS did not appear significantly associated with hypertension history; the median OS was 15.90 months for those with hypertension, compared with 27.80 months in patients without hypertension (P =.38). Response and progression-free survival also did not show significant differences based on hypertension history (P =0.65 for response, and P =.97 for progression-free survival).
The study investigators concluded that they did not find a significant difference in median OS associated with presence or absence of hypertension history in patients with mRCC in this study, even though, as the researchers noted, uncontrolled hypertension is often an exclusion criterion for clinical trials.
Disclosures: Multiple authors declared affiliations with or received funds from the pharmaceutical industry. Please see the original abstract for a full list of disclosures.
Maslov D, Tawagi K, KC M, et al. The impact of hypertension on response rates in patients with renal cell carcinoma. J Clin Oncol. 2021;39(suppl 6):abstr 287. doi:10.1200/JCO.2021.39.6_suppl.287
This article originally appeared on Oncology Nurse Advisor